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Abstract
Over the last two decades, a number of high-throughput technologies (genome- 
and proteome-based) have been developed and applied on different cancer types 
such as squamous cell carcinomas (SCCs) arising from aerodigestive and genito-
urinary tracts. These analyses, when comprehensively utilized, have clearly con-
tributed to a better understanding of the molecular hallmarks, oncogenic pathways 
and immunological features of SCCs. This chapter aims to describe the SCCs most 
important molecular aberrations as well as their molecular classification, highlight-
ing the commonalities and differences among them, independent of their body 
site origin. The most frequently altered oncogene is PIK3CA, involved in the PI3K/
AKT/mTOR pathway and frequently activated in many human cancers. However, 
alterations in the cell-cycle control TP53 gene occur in the vast majority of SCCs. 
New possible molecular therapies, common to all SCCs, are discussed in light of a 
comprehensive, panSCC analysis.
Keywords: squamous cell carcinoma, human papillomavirus, genomics,  
Fanconi anemia, TCGA, mutation, copy number alteration, cancer treatment, biomarker
1. Introduction
Squamous cell carcinomas (SCCs) represent highly common solid cancers that 
arise from stratified and pseudo-stratified epithelia of the skin, and aerodigestive 
and genitourinary tracts. Although SCCs from different body sites share histologi-
cal characteristics, they are molecularly and clinically heterogeneous, and a major 
cause of cancer mortality [1]. Reported risk factors for SCCs, depending on the 
body site, include alcohol intake (head and neck, and esophagus), cigarette smok-
ing (bladder, lung, head and neck, and esophagus), UV light exposure (skin) and 
infection with human papillomavirus (HPV) (skin, head and neck, and cervix 
uteri). HPV infects epithelial cells and transforms them through the oncogene 
action of viral genes. E6 and E7 genes from some HPVs infecting head and neck and 
cervix uteri inhibit the function of the important tumor suppressors p53 and pRb, 
respectively [2, 3]. The initiation of SCCs is due to genomic perturbations, genetic 
mutations, and/or altered expression of key molecules mainly involved in cell-
cycle control, signaling and cell adhesion pathways, squamous differentiation and 
chromatin regulation [1, 4]. A number of reports show that SCCs from different 
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anatomical locations have common features despite the fact that they are clinically 
treated as separate entities. These findings suggest an integrated view of the disease 
and possible new methods for prevention and treatment.
Here we review reports in which hundreds of SCCs have been comprehensively 
characterized at the molecular level using different high-throughput technologies. 
Such analyses highlighted commonalities and differences between SCCs, indepen-
dent of body site origin, and allow their classification based on molecular aberra-
tions. New possible molecular therapies, common to all SCCs, are discussed in light 
of the comprehensive, panSCC analysis.
2. Molecular features of SCCs
SCCs from different anatomical sites have been molecularly characterized using 
various genome-wide technologies (Table 1). Despite early reports describing most 
frequent mutations using next-generation sequencing (NGS) such as whole-exome 
sequencing (WES) in many cancer types [5], most of the comprehensive analyses 
have been done within the context of The Cancer Genome Atlas (TCGA) consortium. 
TCGA is an USA project which has generated comprehensive, multi-dimensional maps 
of the key genomic changes in the main types of cancer (http://cancergenome.nih.
gov/). Microarray- and/or NGS-based technologies have been used in order to deter-
mine mutations in protein coding genes, expression levels of messenger RNA (mRNA) 
and micro RNA (miRNA) molecules, DNA-methylation and genome copy-number 
variation (CNA) (Table 1). Moreover, an important subset of cancers has been charac-
terized at the protein level, using Reverse Phase Protein Array (RPPA) (Table 1).  
Recently, the TCGA launched a set of publications reporting pancancer analyses 
of more than 11,000 tumors from 33 types of cancers [4] (https://www.cell.com/
pb-assets/consortium/pancanceratlas/pancani3/index.html), including SCCs from 5 
individual body sites: lung (LUSC), head and neck (HNSC), esophageal (ESCA), cer-
vical (CESC), and bladder (BLCA) cancers. Most of the molecular features described 
here are based on the TCGA panSCC analysis, in which around 1400 SCCs from those 
body sites were analyzed simultaneously [6]. Although skin SCC is the second most 
frequent cancer in Caucasians [7], no comprehensive, genome-wide analysis has been 
reported. Interestingly, most frequent mutations using NGS-based technologies in skin 
SCC showed many similarities with SCC from other body sites [8, 9].
Body site Sample size (SCC size) Genome-wide molecule* Reference
Head and neck 279 (279) DNA-meth, CNA, DNA-seq, mRNA, miRNA, proteome [10]
Lung 178 (178) DNA-meth, CNA, DNA-seq, mRNA, miRNA [11]
Esophagus 164 (90) DNA-meth, CNA, DNA-seq, mRNA, miRNA, proteome [12]
Cervix uteri 228 (144) DNA-meth, CNA, DNA-seq, mRNA, miRNA, proteome [13]
Bladder 131 (19) DNA-meth, CNA, DNA-seq, mRNA, miRNA, proteome [14]
Bladder 412 (42) DNA-meth, CNA, DNA-seq, mRNA, miRNA, proteome [15]
Pancancer12 3,527 (546) DNA-meth, CNA, DNA-seq, mRNA, miRNA, proteome [16]
Pancancer33 ~10,000 (~1,400) DNA-meth, CNA, DNA-seq, mRNA, miRNA, proteome [4]
PanSCC ~1,400 (~1,400) DNA-meth, CNA, DNA-seq, mRNA, miRNA, proteome [6]
*DNA-meth: DNA methylation; CNA: DNA copy number alteration; DNA-seq: whole exome sequencing; mRNA: 
messenger RNA; miRNA: micro RNA; proteome: reverse phase protein assay (RPPA).
Table 1. 
List of publications with genome-wide analysis of SCC.
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2.1 Mutations in cancer genes
The most frequent mutated gene found in SCCs is TP53 (64% in panSCCs) [4, 6, 16],  
(Figure 1) a tumor suppressor gene whose main function is to prevent genome 
mutations [17]. Missense “hot spots” mutations are very common, which result in 
dominant-negative and/or gain-of-function properties [18]. Although Tp53 was found 
to be highly altered in many other cancer types [19], frequencies depends on the type, 
stage, body site, and other factors. Mutations in TP53 are infrequent in HPV(+) SCC 
cancers, possibly because p53 functions are compromised as the protein is degraded 
by the activity of the viral E6 oncogene. Individually, frequent TP53 mutations are 
found in SCCs within BLCA [15], ESCA [12], HNSC [10] and LUSC [11], and to 
a lesser extent in CESC whereby the majority of tumors are HPV(+) [13]. Other 
mutated genes involved in cell-cycle control include CDK inhibitor CDKN2A and the 
RB1 gene, although less frequently. The incidence of CDKN2A/RB1 mutations is much 
reduced in HPV(+) HNSC and CESC, as the E7 viral oncogene can bind and inacti-
vate pRb protein, coded by RB1, thus rendering direct genetic mutation dispensable 
[10, 13]. Another important group of mutated genes include regulators of squamous 
differentiation, such as NOTCH1, AJUBA or ZNF750 (Figure 1) [4, 6, 16].
Figure 1. 
Relevant mutations and CNA alterations in SCCs from BLCA, CESC, LUSC, HNSC and ESCA. Tumors are 
grouped into iC10, iC25 and iC27 clusters. Genes are grouped into functions. Frequency of alterations per gene 
is shown. HPV infected samples are indicated. Tumors having WES and CNA data, and belonging to iC10, 
iC25 and iC27 clusters are shown (n = 1098). Data are from the cBioportal for Cancer Genomics (http://www.
cbioportal.org/) [20].
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Other mutated genes include KMT2D, NSD1, EP300, or KDM6A, all of them 
involved in chromatin regulation through histone post-translational modifications. 
PIK3CA, PTEN, FAT1, EPHA2 or RASA1 genes, also mutated, are involved in important 
signaling and cell adhesion pathways of epithelial cells. There are also mutations in genes 
important in cell survival, like TGFBR2 or CASP8. Mutations of HLA-A and HLA-B and 
deletions of B2M, implicated in immune escape, also exist (Figure 1) [4, 6, 16].
2.2 panSCC molecular clustering
High-throughput technologies have allowed the identification of tumor sub-
groups within specific cancer types, like the ‘intrinsic subtypes’ of breast cancer [21], 
occasionally having important clinical differences and outcomes [22]. Tumor sub-
groups based on genome-wide molecular analyses have been reported also for HNSC 
[10], LUSC [11], BLCA [14, 15], CESC [13] and ESCA [12]. Such classifications are 
based on molecular features like mutations, CNA, DNA-methylation, or expression 
of mRNAs, miRNAs, proteins [10–15] and long non-coding RNAs [15, 23, 24].
The existence of hundreds of primary tumors from different cancer types within 
TCGA having multiplatform molecular data have allowed the integrated identifica-
tion of their differences and commonalities, regardless of body site [4, 6, 16]. One 
of such analyses, performed over 1400 SCCs from five different locations (LUSC, 
HNSC, CESC, ESCA and BLCA), discovered the existence of different SCC tumor 
clusters based on CNA (six clusters), DNA methylation (five clusters), mRNA 
expression (six clusters), miRNA expression (five clusters), and RPPA-based protein 
expression (eight clusters) [6]. These clusters highlight significant molecular features 
in SCC versus non-SCC, and between SCCs. Moreover, the iClustering method [25], 
which performs clustering from multi-type genomic data, showed the presence of 3 
main iClusters: iC10, iC25 and iC27 [6] (Figure 1). Most HPV(−) tumors grouped in 
iC10 and iC25, associated with smoking history, organ site and molecular aberrations 
(Figure 2A), while most HPV+ CESC and HNSC samples mapped within iC27 having 
non-smoking individuals (Figure 2A). All tree SCC-clusters displayed significant 
chromosome 5q and 3p copy gains, concomitant with overexpression in 3q genes SOX2, 
TP63, and TP73, implicated in squamous differentiation and stemness (Figure 1) [6].  
iC25 cluster bear 11q gains, and iC10/iC25 included 9p losses. Most iC10/25 HPV(−) 
SCC tumors displayed genome-wide hypomethylation with high DNA CNA, and 
associated augmented mRNA and miRNA levels. Some HPV(−) SCCs and most iC27 
HPV(+) HNSCs and CESCs, showed wider hypermethylation and reduced CNAs, 
correlated with reduced mRNA and miRNA expression [6].
Kaplan-Meier curves demonstrated significant differences in overall survival 
and progression-free interval between the iClusters, even after adjusting for 
distinct body sites or disease stages (Figure 2B). Patients within iC25 display poorer 
prognosis, possibly associated to higher CNA aberrations and genome instability 
(Figures 1 and 2B). Therefore, panSCC analysis showed the existence of a prevalent 
SCC group, having a combination of recurrent CNA and other alterations, and 
other subtypes whereby HPV infection and other alterations have a greater role.
2.3 Cancer genes in CN alterations
Oncogenic transformation from normal tissues occurs upon the accumulation of 
small mutations and also larger alterations, giving rise to deletion (DEL) or ampli-
fication (AMP) of regions and altering the normal diploid state of the genome. 
Negative regulators of cell-cycle control like CDKN2A and RB1 are frequently 
deleted in SCCs (Figure 1). Contrarily, CCND1, MYC, and CCNE1 genes appear 
frequently amplified, and therefore, their function in cell proliferation. Important 
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positive mediators of signaling and cell adhesion pathways are frequently ampli-
fied (EGFR, ERBB2, FGFR1, PIK3CA, AKT1, AKT3, MAPK1, YAP1), and tumor 
suppressors like PTEN or FAT1 are deleted. Chromosome 3q genes TP63 and SOX2 
are highly frequently co-amplified, and overexpression of their mRNAs is a com-
mon SCC feature as mentioned above (Figure 1) [6]. Squamous differentiation 
genes which are deleted also exist, like NOTCH1 and ZNF750. Frequent deletion of 
chromatin regulation genes occurs, like ARID1A, NSD1, KMT2C or KDM6A. There 
are also alterations in cell survival genes, like NFE2L2 (AMP), BCL2L1 (AMP), and 
BCL2L2 (DEL). Importantly, some main immune escape regulators are segregated 
in CNA regions, like PD-L1 (AMP) or B2M (DEL) (Figure 1).
3. SCC and Fanconi DNA repair pathway
Fanconi anemia (FA) is a rare autosomal recessive genetic disorder in which 
patients can develop a life-threatening bone marrow failure in the early years after 
birth [27], which frequently requires allogeneic hematopoietic stem cell transplant 
[28]. In addition to this blood disorder, FA patients can develop leukemias and 
solid tumors, mainly SCC in the head and neck, skin, and anogenital regions [29]. 
Figure 2. 
Clinical features of main panSCC iClusters, including body site distribution and patient smoking history 
frequencies within each iC10, iC25 and iC27 (A), and survival curves with 2 endpoints: overall survival and 
progression-free interval (B). Clinical data obtained from Liu et al. [26]. P-values were calculated after 
multivariate Cox regression analysis, using iClusters and body sites or pathologic tumor stage.
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Figure 3. 
Mutations and deep deletion in all 22 FA pathway genes in SCCs from BLCA, CESC, LUSC, HNSC and 
ESCA. (A) Tumors are grouped into iC10, iC25 and iC27 clusters. Frequency of alterations per gene is shown. 
HPV infected samples are indicated. (B) Alteration frequency in any FA gene is shown per body site. Tumors 
having WES and CNA data, belonging to iC10, iC25 and iC27 clusters, and having mutation/deep deletion are 
shown (n = 314). Data are from the cBioportal for Cancer Genomics (http://www.cbioportal.org/) [20].
Incidence of HNSC in FA is >500 times higher than in the general population, and 
average age of appearance is significantly earlier. Mutations occur in genes involved 
in the ‘FA pathway’ which is activated as a result of DNA replication or DNA dam-
age, especially the damage triggered from DNA crosslinking agents. Some of these 
FA genes include BRCA1 and BRCA2 genes, well known breast cancer-susceptibility 
genes. Hitherto, there is no explanation for the high incidence of FA-HNSC, but it 
has been suggested that FA pathway defects might accelerate oncogenic transforma-
tion through the accumulation of mutations in a DNA repair-defective context [30]. 
In this sense, a number of reports showed tumor suppressor functions by FA genes, 
both in the FA as well as in non-FA human cancer [31].
Campbell et al. reported an unexpectedly high frequency (around 12%) of 
molecular aberrations involving top 10 FA pathway genes in panSCC from TCGA 
[6]. An analysis using all 22 FA pathway genes reported so far, demonstrated that 
almost 30% of SCCs within iC10, iC25 and iC27 clusters from BLCA, CESC, ESCA, 
HNSC and LUSC (314 out of 1098) display either point mutations or deletions in 
any FA gene (Figure 3). Whether all of these FA gene alterations are associated with 
defects in DNA-repair is unknown, but clinical implications would be important 
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as the FA pathway is a major predictor of cisplatin response in HNSC [32]. These 
findings suggest that acquired as well as germline alterations in this pathway may 
contribute to the development of a subset of SCC.
4. Molecular therapies against SCC
Patients suffering squamous cell carcinoma display poor overall survival, and 
the disease is difficult to treat. Independent of body site, the standard of care is 
based on surgery, radiotherapy and chemotherapy. Still, few molecular therapies 
are being used so far, and only in the latest stages of the disease, such as immuno-
therapies, cetuximab (antibody to EGFR) in HNSC or bevacizumab (antibody to 
VEGF) in cervical cancer. There is a clear need to develop new targeted therapies 
accompanied with accurate response biomarkers, so we can give more effective 
and less aggressive treatments to SCC patients. The profound knowledge about the 
molecular biology of SCCs that we have acquired over the last recent years, together 
with comparative efforts of tumors from different body sites, should help to design 
new clinical trials challenging current treatment modalities.
4.1 Immunotherapies in SCCs
As understanding of the underlying cancer biology and the complex interactions 
within the tumor microenvironment improves, there is gathering interest in and 
evidence for the role of immunomodulating agents in the management of cancer. 
Immune checkpoint inhibitors, which aim to hinder the inhibitory interaction 
between programmed cell death protein 1 (PD-1) and its ligand PD-L1, have dem-
onstrated durable improvements in patient outcomes in many cancer types. Thus, 
pembrolizumab (anti-PD1) has been approved to treat HNSC, CESC, LUSC, and 
BLCA [33–35]. Clinical trials for pembrolizumab in ESCA are giving good responses 
[36]. Nivolumab has also reach FDA approval for HNSC, BLCA and LUSC [33–35]. 
Other existing immunotherapies include avelumab, atezolizumab and durvalumab 
for BLCA [34]. Although the use of immunomodulating agents in SCC treatment 
is giving good results, none of them are being used in first line so far and many 
patients do not respond. Therefore, future analyses and trials should focus on devel-
oping accurate response predictors to accelerate their use as first line in therapy.
4.2 Possible new therapies targeting SCCs biomarkers
Deep molecular analyses of SCCs, as explained above, suggest that certain 
targeted therapies, at different stages of clinical trial or approval, might be adequate 
for SCC treatment. These include targeting the following biomarkers:
i. PIK3CA, which encodes p110α, a catalytic subunit of phosphoinositide 3-kinase 
(PI3K). Activated PI3K can activate PDK1 and AKT, triggering downstream 
effects on transcription, protein synthesis, metabolism, proliferation and 
apoptosis. The gene is amplified or mutated in about 37% of SCCs (Figure 1), 
and constitutes the most frequently mutated oncogene in cancers like HNSC, 
CESC, ESCA and LUSC. A number of clinical trials with p110α inhibitors as 
possible antitumor therapies are currently running. We have recently identified 
that HPV(−), HNSC tumors that overexpress PIK3CA display poor outcome 
and activation of the YAP1-nuclear function, a transcriptional co-factor within 
the Hippo growth pathway [37]. Therapies targeting nuclear YAP1 might also 
be effective in a subgroup of SCC patients [38].
Squamous Cell Carcinoma - Hallmark and Treatment Modalities
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ii. CCND1, which encodes cyclin D1, is a cell-cycle protein that regulates 
transition from G1-to-S phase through the formation of complexes with 
cyclin dependent kinases (CDKs), such as CDK4 and CDK6. CCND1 
is amplified in 20% of panSCCs, and in 93% within the iCluster iC25 
(Figure 1). CCND1 amplification is associated with poor prognosis, cis-
platin resistance and EGFR-inhibitor resistance in HNSC [39]. Although 
targeting of cyclin D1 is not currently feasible, there are inhibitors of 
its binding partners CDK4/CDK6, which might be useful in the CCND1 
amplification setting [40].
iii. CDKN2A, which encodes p16INK4A, is a CDK4/CDK6 inhibitor that regulates 
cell-cycle. CDKN2A is mutated or deleted in 43% of panSCCs, mostly in the 
iC25 cluster (50%) (Figure 1). Similar to CCND1 amplified tumors, CDKN2A 
mutated/deleted tumors might respond to CDK4/CDK6 inhibitors [40].
iv. EGFR, which encodes the epidermal growth factor receptor protein, is 
mutated or amplified in 11% of panSCCs, mainly in HPV(−) tumors. 
Although EGFR is an attractive target for therapy by either small-mol-
ecule inhibitors [41] or blocking antibodies [42], current EGFR-related 
therapies in SCC are limited to cetuximab antibody in HNSC. Good 
responses are observed to inhibitors in lung tumors with activating EGFR 
mutations, but they occur in adenocarcinomas not in lung SCCs. Further 
research should be done with EGFR-therapies in panSCCs, understanding 
mechanisms of action as well as probing response efficacy in preclinical 
models.
5. Conclusions
Squamous cell carcinomas arising from five different body sites (bladder, 
cervix uteri, lung, head and neck, and esophagus) share many molecular aberra-
tions, so that the majority of them can be classified in 3 main molecular clusters 
(iC10, iC25 and iC27). Principal differences between clusters include HPV 
infection, genome-wide DNA-methylation and CNA, and mutations/CNA in 
subsets of cancer genes. Amplification in CCND1 is prevalent in iC25 samples, 
and TP53 and CDKN2A deleterious modifications in HPV(−) tumors. iC25 
tumors are HPV(−), display frequent genome alterations and smoking patients, 
as well as poorer clinical outcome. Importantly, there exist common features 
between panSCC clusters, such as oncogene PIK3CA mutations/amplifications, 
amplification in TP63 and SOX2, or mutations in chromatin modifier regulators 
(like KMT2C and KMT2D). The comprehensive, panSCC molecular analyses 
suggest that current and future clinical trials targeting aberrations in signaling/
cell adhesion pathways (PIK3CA and EGFR inhibitors) and cell-cycle control 
(CDK4/CDK6 inhibitors) might have a great impact on SCC treatment and inde-
pendently of their body site. Future research efforts should focus on developing 
accurate biomarkers of immunotherapies. Finally, basic and clinical investigators 
should work together to discover SCC vulnerabilities and derive new treatments, 
as well as understanding basic mechanisms of oncogenesis, tumor progression 
and therapy resistance.
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